NCT02621606View on ClinicalTrials.gov

[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 8, 2016

Primary Completion Date

December 28, 2017

Study Completion Date

December 28, 2017

Conditions
Alzheimer's Disease
Interventions
DRUG

[11C]MK-6884

IV bolus dose of \~370 MBq \[11C\]MK-6884

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02621606 - [11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001) | Biotech Hunter | Biotech Hunter